Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The osmotic release oral system (OROS) methylphenidate formulation is a prolonged-release medication for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. We conducted a seven-week open-label extension of a double-blind study to assess the safety and tolerability of OROS methylphenidate in a flexible dose regimen (18-90 mg daily) for the treatment of adults diagnosed with ADHD (N =370). Medication was adjusted to optimize efficacy and tolerability for each patient. Adverse events, vital signs, and laboratory parameters were assessed. Most patients (337; 91%) completed the seven-week treatment and the final dispensed dose was 18 mg (8%), 36 mg (29%), 54 mg (34%), 72 mg (20%), or 90 mg (9%). Adverse events were reported in 253 (68%) patients and most were mild or moderate in severity; most frequently reported included headache (17%), decreased appetite (13%), and insomnia (11%). Adverse events were rarely serious (<1%; 2/370). Small mean increases in systolic and diastolic blood pressure (both 2.4 mmHg) and pulse (3.2 bpm) were observed. Body weight decreased slightly (-1.5 kg). The results provide additional support for the safety and tolerability of prolonged-release OROS methylphenidate in a flexible dose regimen (18-90 mg/day) for the treatment of adults with ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Kessler, R. C., Adler, L. A., Barkley, R., Biederman, J., Conners, C. K., Faraone, S. V., Greenhill, L. L., Jaeger, S., Secnik, K., Spencer, T., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.001 · Cited by 663
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
SANDRA KOOIJ, J. J., BUITELAAR, J. K., van den OORD, E. J., FURER, J. W., TH. RIJNDERS, C. A., & HODIAMONT, P. P. G. (2005) · Psychological Medicine · doi:10.1017/s003329170400337x · Cited by 468
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378
Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0549-0 · Cited by 375
ADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331
Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., & Webb, C. L. (2008) · Circulation · doi:10.1161/circulationaha.107.189473 · Cited by 296 · cited 1×
“As discussed in guidelines for the use of these medications for the treatment of ADHD in children and adults, the potential cardiovascular effects are generally considered acceptable and manageable and can be monitored as the physician feels necessary.(9,31) As well, all drug products for the treatment of ADHD provide…”
Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M., & Spencer, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.011 · Cited by 267
Nutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259 · cited 1×
“As discussed in guidelines for the use of these medications for the treatment of ADHD in children and adults, the potential cardiovascular effects are generally considered acceptable and manageable and can be monitored as the physician feels necessary.(9,31) As well, all drug products for the treatment of ADHD provide…”
Cited by
Groenman, A. P., Schweren, L. J. S., Dietrich, A., & Hoekstra, P. J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1301928 · Cited by 46
Cornforth, C., Sonuga-Barke, E., & Coghill, D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791959827 · Cited by 41
“There is also a similar safety profile [124].”
BackgroundCasas, M., Rösler, M., Sandra Kooij, J. J., Ginsberg, Y., Ramos-Quiroga, J. A., Heger, S., Berwaerts, J., Dejonckheere, J., van der Vorst, E., & Schäuble, B. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.600333 · Cited by 38
“LAMDA-II (EudraCT #: 2007-002111-82) was a double-blind, randomized, placebo-controlled, fi xeddose study conducted at 42 European sites between February 2008 and April 2009.”
BackgroundResultInfluentialContini, V., Rovaris, D. L., Victor, M. M., Grevet, E. H., Rohde, L. A., & Bau, C. H. D. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.006 · Cited by 34
Metadata
- Authors
- Challis
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2009-08
- Volume
- 5
- Pages
- 457
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2137859389
- Cited by
- 23
- References
- 20
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.